BioTuesdays

Category - Markets

Aurinia Pharmaceuticals
Markets

Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20. Analyst Joseph Schwartz writes...

October 23, 2017
Nightstar Therapeutics
Markets

Leerink starts Nightstar at OP

Leerink initiated coverage of Nightstar Therapeutics (NASDAQ:NITE) with an “outperform” rating and $25 price target. The stock closed at $19 on Oct. 20. Nightstar is harnessing the potentially curative properties of...

October 23, 2017
Gemphire Logo
Markets

Roth starts Gemphire at buy

Roth Capital Markets launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and 12-month price target of $30. The stock closed at $9.54 on Oct. 18. “Our rating on Gemphire is driven by our...

October 19, 2017
Eiger BioPharmaceuticals Logo
Markets

Roth starts Eiger Biopharma at buy

Roth Capital Partners initiated coverage of Eiger Biopharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $35 price target. The stock closed at $11.65 on Oct. 18. Analyst Michael Higgins writes that the company is...

October 19, 2017
Madrigal Pharmaceuticals
Markets

Roth starts Madrigal Pharma at buy

Roth Capital Partners launched coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a “buy” rating and a 12-month price target of $62. The stock closed at $47.52 on Oct. 18. “Our rating on Madrigal shares is based on...

October 19, 2017
Galectin Therapeutics
Markets

Roth starts Galectin at buy

Roth Capital Partners initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and a 12-month price target of $8. The stock closed at $2.51 on Oct. 18. “Our rating on Galectin shares is based on our...

October 19, 2017
Ignyta
Markets

Ladenburg ups Ignyta price target to $31

Ladenburg Thalmann raised its price target for Ignyta (NASDAQ:RXDX) to $31 from $20.25 based on expectations for entrectinib to be first line therapy for ROS1+ non-small cell lung cancer (NSCLC). The stock was changing...

October 18, 2017
Audentes
Markets

WB starts Audentes Therapeutics at OP

William Blair initiated coverage of Audentes Therapeutics (NASDAQ:BOLD) with an “outperform” rating and $35 fair value estimate. The stock closed at $25 on Oct. 16. Analyst Raju Prasad writes that the company is taking...

October 17, 2017
Ardelyx
Markets

Leerink resumes coverage of Ardelyx at OP

Leerink resumed coverage of Ardelyx (NASDAQ:ARDX) with an “outperform” rating and $13 price target. The stock closed at $6.40 on Oct. 16. Analyst Seamus Fernandez writes that in the last nine months, the clinical...

October 17, 2017
Flex Pharma
Markets

Flex Pharma starts Phase 2 CMT trial

Flex Pharma (NASDAQ:FLKS) has initiated a Phase 2 double-blinded, parallel design trial in the U.S., known as COMMIT, to evaluate FLX-787, its co-activator of TRPA1 and TRPV1, in patients with Charcot-Marie-Tooth, who...

October 16, 2017